PDF(Pubmed)
Abstract：
The fight against infectious disease has remained an ever-evolving challenge in the landscape of healthcare. The ability of pathogens to develop resistance against conventional drug treatments has decreased the effectiveness of therapeutic interventions, and antibiotic resistance is recognized as one of the main challenges of our time. The goal of this systematic review paper is to provide insight into the research papers published on innovative nanosized drug delivery systems (DDSs) based on gentamycin and vancomycin and to discuss the opportunity of their repurposing through nano DDS formulations. These two antibiotics are selected because (i) gentamicin is the first-line drug used to treat suspected or confirmed infections caused by Gram-negative bacterial infections and (ii) vancomycin is used to treat serious Gram-positive bacterial infections. Moreover, both antibiotics have severe adverse effects, and one of the purposes of their formulation as nanosized DDSs is to overcome them. The review paper includes an introduction focusing on the challenges of infectious diseases and traditional therapeutic treatments, a brief description of the chemical and pharmacological properties of gentamicin and vancomycin, case studies from the literature on innovative nanosized DDSs as carriers of the two antibiotic drugs, and a discussion of the results found in the literature.
摘要：
在医疗保健领域，与传染病的斗争仍然是一个不断发展的挑战。病原体对常规药物治疗产生耐药性的能力降低了治疗干预措施的有效性，抗生素耐药性被认为是我们这个时代的主要挑战之一。这篇系统综述论文的目的是提供对基于庆大霉素和万古霉素的创新纳米药物递送系统（DDS）发表的研究论文的见解，并讨论通过纳米DDS制剂重新利用它们的机会。选择这两种抗生素是因为(i)庆大霉素是用于治疗由革兰氏阴性细菌感染引起的疑似或确认感染的一线药物,以及(ii)万古霉素用于治疗严重的革兰氏阳性细菌感染。此外，两种抗生素都有严重的不良反应，并且将其配制为纳米尺寸DDS的目的之一是克服它们。这篇综述论文包括一个介绍，重点是传染病和传统治疗方法的挑战，简要描述庆大霉素和万古霉素的化学和药理特性，来自创新纳米DDS作为两种抗生素药物载体的文献的案例研究，并讨论了文献中的结果。
